A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis

Current Medical Research and Opinion

Volumn 28, Issue 3, 2012, Pages 385-394

  Chen, Minjie ^a   Gong, Lan ^a   Sun, Xinghuai ^a   Gu, Yangshun ^b   He, Xiangge ^c   Qu, Jia ^d   Wang, Lili ^e   Zhang, Mingzhi ^f   Zhong, Xingwu ^g  

^a FUDAN UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Medical College   (China)

^e NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

Blepharokeratoconjunctivitis; Dexamethasone; Intraocular pressure; Loteprednol etabonate; Safety; Tobramycin

Indexed keywords

DEXAMETHASONE PLUS TOBRAMYCIN; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN;

ADULT; AGED; ALOPECIA; APPLICATION SITE DRYNESS; APPLICATION SITE PAIN; ARTICLE; BACTERIAL KERATITIS; BLEPHAROKERATOCONJUNCTIVITIS; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSTILLATION SITE STINGING; INTRAOCULAR PRESSURE; KERATITIS; KERATOCONJUNCTIVITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLIT LAMP; SPINE DISEASE; SUPERFICIAL PUNCTATE KERATITIS; SYMPTOM; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; ANDROSTADIENES; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; KERATOCONJUNCTIVITIS; MALE; MIDDLE AGED; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84863280798     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.659723     Document Type: Article

References (30)

1. Viswalingam M, Rauz S, Morlet N, et al. Blepharokeratoconjunctivitis in children: Diagnosis and treatment. Br J Ophthalmol 2005;89:400-3
2. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205
3. Armaly MF. Effects of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-91
4. Burde RM, Becker B. Corticosteroid-induced glaucoma and cataracts in contact lens wearers. JAMA 1970;213:2075-7
5. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-7
6. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992;9:1275-8
7. The Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol 1999;127:537-44
8. Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993; 9:157-65
9. Dell SJ, Shulman DG, Lowry GM, et al, for the Loteprednol Allergic Conjunctivitis Study Group. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997;123:791-7
10. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998;102:251-5
11. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30:10-13
12. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999;106:362-9
13. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inFammation. Loteprednol Etabonate Post-operative InFammation Study Group 1. J Cataract Refract Surg 1998;24:1480-9
14. The Loteprednol Etabonate Postoperative InFammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inFammation. The Loteprednol Etabonate Postoperative InFammation Study Group 2. Ophthalmology 1998;105:1780-6
15. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-21
16. Friedlaender MH, Howes J, for the Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. A double-masked, placebo-controlled evaluation of the efEcacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997;123:455-64
17. PFugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138:444-57
18. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24:287-96
19. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://wma/net/en/policy/b3.htm. Accessed September 6, 2011
20. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharokeratoconjunctivitis. Adv Ther 2007;24:60-7
21. Torkildsen GL, Cockrum P, Meier E, et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin 2011;27:171-8
22. Kuo A, Mah F. Evaluation of topical tobramycin/dexamethasone and tobramycin/loteprednol in the management of blepharokeratoconjunctivitis [abstract]. Invest Ophthalmol Vis Sci 2005;46(Suppl 5):2673
23. Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7:266-9
24. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycindexamethasone with dexamethasone-neomycin-polymyxin and neomycinpolymyxin- gramicidin for control of inFammation after cataract surgery: Results of a multicenter, prospective, three-arm, randomized, doublemasked, controlled, parallel-group study. Clin Ther 2004;26:1274-85
25. Bucala R, Gallati M, Manabe S, et al. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res 1985;40:853-63
26. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984;74:1803-10
27. Chang DF, Tan JJ, Tripodis Y. Risk factors for steroid response among cataract patients. J Cataract Refract Surg 2011;37:675-81
28. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112:593-8
29. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-7
30. Shukla D, Vidhya N, Prasad NM, et al. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol 2007;144:453-4